Given that local delivery of the NgR(310)-Fc fusion protein to several injury sites has demonstrated repair outcomes in animal models there is solid rationale to pursue this therapeutic regime within the animal model of MS, EAE. Here, RTN4R is linked to myeloid sarcoma.